Scholarlink

<p>Surface-enhanced Raman scattering (SERS) sensors represent a transformative analytical platform for environmental and biochemical monitoring due to the unparalleled sensitivity. In clinical oncology, aberrant expression of the human tumor protein TP63 gene correlates strongly with diverse malignancies, including head and neck, lung, breast, and bladder cancers. Consequently, TP63 can be served as a critical biomarker for early cancer diagnosis and risk assessment. This study introduces a novel SERS sensor for TP63 gene detection, leveraging a dual-nanostructure design comprising gold nanoshells (AuNSs) and gold nanoparticles (AuNPs). The sensor employs sandwich hybridization of DNA probes for target capture, with dipyrido[3,2-a:2’,3’-c]phenazine (DPPZ) intercalated into double-stranded DNA as a SERS reporter. The AuNSs/AuNPs architecture generates plasmonic hotspot that amplify Raman signals, enabling detection limits of 8 pM and a linear dynamic range spanning four orders of magnitude (50 pM–500 nM). Specificity validation confirmed robust discrimination against single-base (26% signal reduction) and three-base mismatched (69% reduction) sequences. Size-dependent optimization of AuNPs further refined the sensor performance, achieving detection limits as low as 3.7 pM. These results demonstrate that the sensor possesses the potential for clinical deployment in malignancy screening and molecular diagnostics.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A SERS Sensor Based on Gold Nanoshell-Gold Nanoparticles for Sensitive Detection of TP63 Gene

  • 期刊论文

  • 发表日期：

    2025年12月17日

查看全文
  • Qian Chen,
  • Peng Shen,
  • Dingting Zhao,
  • Min Wu,
  • Li Zhu

摘要

Surface-enhanced Raman scattering (SERS) sensors represent a transformative analytical platform for environmental and biochemical monitoring due to the unparalleled sensitivity. In clinical oncology, aberrant expression of the human tumor protein TP63 gene correlates strongly with diverse malignancies, including head and neck, lung, breast, and bladder cancers. Consequently, TP63 can be served as a critical biomarker for early cancer diagnosis and risk assessment. This study introduces a novel SERS sensor for TP63 gene detection, leveraging a dual-nanostructure design comprising gold nanoshells (AuNSs) and gold nanoparticles (AuNPs). The sensor employs sandwich hybridization of DNA probes for target capture, with dipyrido[3,2-a:2’,3’-c]phenazine (DPPZ) intercalated into double-stranded DNA as a SERS reporter. The AuNSs/AuNPs architecture generates plasmonic hotspot that amplify Raman signals, enabling detection limits of 8 pM and a linear dynamic range spanning four orders of magnitude (50 pM–500 nM). Specificity validation confirmed robust discrimination against single-base (26% signal reduction) and three-base mismatched (69% reduction) sequences. Size-dependent optimization of AuNPs further refined the sensor performance, achieving detection limits as low as 3.7 pM. These results demonstrate that the sensor possesses the potential for clinical deployment in malignancy screening and molecular diagnostics.